What Is Happening in Asthma Research Right Now
The landscape of asthma treatment research has shifted noticeably over the past several years. Pharmaceutical companies and academic medical centers are investing heavily in understanding why certain people respond well to one medication while others struggle despite following the same regimen. A major area of focus involves biologic therapies, which are medications designed to target very specific inflammatory pathways rather than applying a broad approach to symptom control.
In April 2026, the FDA approved Breztri Aerosphere as a maintenance treatment for asthma in patients aged 12 and older, making it the first triple-combination therapy delivered through a single inhaler for this condition. The approval came out of the Phase III KALOS and LOGOS trials, which demonstrated measurable improvements in lung function compared to dual therapy approaches. This matters because it illustrates how clinical research directly translates into new options at the pharmacy.
Another development worth noting comes from the PASSAGE study, a Phase IV real-world trial evaluating tezepelumab across diverse patient populations that are often excluded from traditional research. The study specifically included Black and African American participants, adolescents, individuals with a history of smoking, and people with concurrent mild to moderate COPD. Results presented at the 2026 American Thoracic Society conference showed reduced exacerbation rates across all subgroups, with particularly encouraging outcomes for patients with Type 2 asthma, a subtype driven by systemic inflammation.
Researchers are also exploring novel mechanisms. Eli Lilly's brenipatide, currently in Phase II trials for moderate to severe uncontrolled asthma, takes a different approach by targeting incretin pathways, an area more commonly associated with metabolic research. Meanwhile, PRA-216 is being investigated in early-phase studies that include both healthy volunteers and participants with mild to moderate asthma, reflecting the methodical stepwise process that all experimental therapies must undergo.
How Clinical Trial Phases Work and Why They Matter
Understanding the phase system helps demystify what researchers are trying to accomplish at each stage.
Phase I studies involve small groups, often healthy volunteers initially, and focus primarily on safety, dosing, and how the body processes the investigational product. For asthma specifically, Phase I trials sometimes include participants with mild disease to observe early signals of how the drug behaves in the target population.
Phase II expands to a larger group of people who actually have the condition being studied. The goal shifts toward determining whether the treatment shows enough promise to justify a much larger investment. Dose levels are refined here, and researchers start gathering preliminary efficacy data.
Phase III trials are the large, often multinational studies that generate the evidence package submitted to the FDA for approval. These trials typically involve hundreds or thousands of participants across dozens of sites in multiple countries, including locations throughout the United States. The KALOS and LOGOS trials mentioned earlier fall into this category.
Phase IV studies happen after approval and examine how a treatment performs in broader, more diverse populations under real-world conditions. The PASSAGE study is a recent example, deliberately recruiting patients who might have been excluded from earlier trials, such as those with a significant smoking history or coexisting lung conditions.
The table below summarizes what patients might encounter at each phase.
| Phase | Typical Enrollment | Duration | Key Focus | Patient Involvement |
|---|
| Phase I | 20–100 participants | Weeks to months | Safety and dosing | May require extended clinic stays for monitoring |
| Phase II | 100–500 participants | Several months to a year | Efficacy signals and dose refinement | Regular clinic visits, typically every 2–4 weeks |
| Phase III | 500–3,000+ participants | 1–3 years | Confirmatory evidence for approval | Similar visit schedule to standard specialist care |
| Phase IV | Varies widely | 1–5 years | Real-world effectiveness and long-term safety | Often less frequent visits than earlier phases |
Who Qualifies and What to Expect
Eligibility criteria vary considerably from study to study, but certain patterns appear across many asthma trials. Researchers typically look for participants whose asthma remains inadequately controlled despite using standard maintenance medications. This might mean someone using a medium-to-high dose inhaled corticosteroid plus a long-acting beta agonist who still experiences flare-ups or daily symptoms.
Common inclusion criteria include a documented asthma diagnosis of at least six to twelve months, measurable airflow limitation on spirometry, and a history of exacerbations within the past year. Many trials set an age range of 18 to 75, though pediatric studies recruit younger participants, and the Breztri approval specifically covered adolescents aged 12 and older.
Exclusion criteria often rule out current smokers or those with a smoking history exceeding a certain threshold, typically 10 pack-years. Other disqualifying factors may include recent respiratory infections, certain coexisting medical conditions, or pregnancy.
Maria, a 42-year-old teacher from Ohio, enrolled in a biologic therapy trial after years of cycling through inhalers that left her short of breath climbing stairs. "I was nervous about being a guinea pig," she recalls, "but the study team walked me through every step. I had more monitoring during that year than I ever got in regular care, and my exacerbations dropped from four per year to none." Her experience reflects what many trial participants report: the intensity of attention and monitoring during a study often exceeds what routine clinical practice provides.
The practical commitment varies. Some trials require monthly injection visits, while others involve daily oral medications with periodic check-ins. Participants should expect to complete symptom diaries, undergo regular spirometry testing, and in some cases provide blood samples. Travel to study sites can be a significant consideration, particularly for people living in rural areas where academic medical centers may be hours away.
Compensation, Costs, and Practical Considerations
A question that comes up in nearly every conversation about clinical trial participation is whether patients get paid. The short answer is that many studies do provide compensation, but the structure and amount vary. Compensation typically covers time and travel rather than serving as a financial incentive to accept medical risk. Payments might be structured per completed visit, with amounts that reflect the burden of each visit type.
Industry-sponsored trials tend to offer more consistent compensation than investigator-initiated academic studies. Research published in 2025 examining practices at a California academic institution found that studies conducted at public hospitals and clinics were more likely to provide compensation than those at university hospitals. The same analysis noted that unfunded studies were less likely to offer payment.
Beyond compensation, participants should understand what costs they will not bear. The investigational product itself is provided at no charge. Study-related procedures, including lab work, imaging, and specialist assessments, are covered by the sponsor. Standard asthma medications that participants continue taking during the trial typically remain their responsibility through insurance or out-of-pocket payment, which is an important detail to clarify during the informed consent process.
Insurance considerations deserve attention. Federal law generally requires health plans to cover routine patient care costs associated with clinical trials, but the specifics can get complicated. Patients should contact their insurer to confirm coverage before enrolling, and many research sites have staff who help navigate these conversations.
Finding Trials and Making an Informed Decision
The starting point for most people is ClinicalTrials.gov, a database maintained by the National Library of Medicine that lists studies across all 50 states. The site allows filtering by condition, location, phase, and recruitment status. Typing "asthma" and a city or state into the search bar typically returns dozens of active or recruiting studies, though narrowing results by specific criteria such as "moderate to severe" or "pediatric" produces a more manageable list.
Academic medical centers with strong pulmonary research programs are concentrated in certain regions. Major hubs include Boston, New York, the Research Triangle area of North Carolina, Houston, the San Francisco Bay Area, and Los Angeles. However, community-based research sites have expanded access considerably, and many trials now include satellite locations in smaller cities.
The American Lung Association maintains resources that help patients understand what participation entails, and local chapters sometimes connect individuals with research opportunities. Patient advocacy organizations focused on asthma and allergic conditions also aggregate trial listings and provide educational materials.
Questions worth asking before enrolling include: What phase is this study, and what is already known about the treatment? How many visits will be required, and how long is each? What happens if my asthma worsens during the trial? Will I have access to the treatment after the study ends? What are the known side effects from earlier research? These questions are best addressed during the informed consent discussion, which should happen before any study procedures begin.
Weighing the Decision
Joining a clinical trial is not the right path for everyone. Some people prefer the predictability of established treatments, and that is entirely reasonable. Others find that the possibility of accessing a therapy not yet available to the public, combined with contributing to knowledge that might help fellow patients, makes the commitment worthwhile.
James, a 58-year-old retiree in North Carolina who participated in a Phase III trial for a biologic after years of oral steroid dependence, puts it plainly: "I did not expect a miracle, and I did not get one. But I did get a treatment that cut my steroid use by more than half, and I got to work with doctors who listened more carefully than anyone I had seen before. That alone changed how I manage my asthma, even after the trial ended."
The decision ultimately rests on a clear-eyed assessment of personal health goals, the specific study's design and requirements, and a candid conversation with both the research team and one's own healthcare provider. Asthma clinical trials in the United States continue to expand in both number and sophistication, offering options that did not exist even a few years ago for people whose symptoms remain stubbornly difficult to control.
研究の知恵